SYLVANT

PeakmAb

siltuximab

BLAINJECTIONINJECTABLEPriority Review
Approved
Apr 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
12

Mechanism of Action

Interleukin-6 Antagonists

Pharmacologic Class:

Interleukin-6 Antagonist

Clinical Trials (5)

NCT06447376Phase 1Recruiting

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

Started Jan 2025
20 enrolled
Non-Hodgkin LymphomaCytokine Release Syndrome
NCT06679829Phase 2Recruiting

A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant

Started Nov 2024
215 enrolled
Multiple Myeloma
NCT04838860Phase 2Terminated

Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease

Started Mar 2021
22 enrolled
Idiopathic Multicentric Castleman's Disease
NCT04616586Phase 3Terminated

SILtuximab in Viral ARds (SILVAR) Study

Started Nov 2020
555 enrolled
Acute Respiratory Distress SyndromeLung DiseasesPneumonia+2 more
NCT04191421Phase 1/2Completed

Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer

Started Jan 2020
35 enrolled
Metastatic Pancreatic AdenocarcinomaStage IV Pancreatic Cancer AJCC v8